TipRanks
Dyne Therapeutics (DYN)
NASDAQ:DYN
US Market
DYN
Dyne Therapeutics
RESEARCH TOOLSreports
Want to see DYN full AI Analyst Report?

Dyne Therapeutics (DYN) Stock Forecast & Price Target

488 Followers
See the Price Targets and Ratings of:

DYN Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
0 Hold
1 Sell
Based on 14 analysts giving stock ratings to
Dyne
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$34.67
▲(31.61% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $34.67 with a high forecast of $50.00 and a low forecast of $10.00. The average price target represents a 31.61% change from the last price of $26.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","30":"$30","51":"$51","19.5":"$19.5","40.5":"$40.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19.5,30,40.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.82,18.44923076923077,21.07846153846154,23.707692307692305,26.336923076923078,28.966153846153844,31.595384615384614,34.22461538461538,36.85384615384615,39.48307692307692,42.112307692307695,44.74153846153846,47.37076923076923,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.82,17.26974358974359,18.719487179487178,20.16923076923077,21.61897435897436,23.068717948717946,24.518461538461537,25.968205128205128,27.41794871794872,28.867692307692305,30.317435897435896,31.767179487179483,33.216923076923074,{"y":34.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.82,15.372307692307693,14.924615384615384,14.476923076923077,14.02923076923077,13.581538461538461,13.133846153846154,12.686153846153847,12.23846153846154,11.79076923076923,11.343076923076923,10.895384615384614,10.447692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.18,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.82,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$34.67Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DYN
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$50→$32
Buy
21.49%
Upside
Reiterated
09/30/26
Dyne Therapeutics price target lowered to $32 from $50 at H.C. WainwrightDyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
Stifel Nicolaus Analyst forecast on DYN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$37
Buy
40.47%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Medios AG (Other OTC: MEDOF) and Dyne Therapeutics (NASDAQ: DYN)
LifeSci Capital Analyst forecast on DYN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$40
Buy
51.86%
Upside
Reiterated
09/30/26
Dyne Therapeutics: Growing Clinical Evidence for z-basivarsen Supports Outperform/Buy Rating and Maintained $40 Price Target
Piper Sandler Analyst forecast on DYN
Edward Tenthoff
Piper Sandler
Piper Sandler
$47
Buy
78.44%
Upside
Reiterated
09/29/26
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Raymond James Analyst forecast on DYN
Martin Auster
Raymond James
Raymond James
$37
Buy
40.47%
Upside
Reiterated
09/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on DYN
Michael Ulz
Morgan Stanley
Morgan Stanley
$45→$36
Buy
36.67%
Upside
Reiterated
09/09/26
Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Robert W. Baird Analyst forecast on DYN
Brian Skorney
Robert W. Baird
Robert W. Baird
$30→$26
Buy
-1.29%
Downside
Reiterated
09/09/26
Dyne Therapeutics price target lowered to $26 from $30 at BairdDyne Therapeutics price target lowered to $26 from $30 at Baird
Jefferies Analyst forecast on DYN
Andrew Tsai
Jefferies
Jefferies
$50
Buy
89.83%
Upside
Reiterated
09/08/26
Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy
J.P. Morgan Analyst forecast on DYN
Tessa Romero
J.P. Morgan
J.P. Morgan
$10
Sell
-62.03%
Downside
Downgraded
09/08/26
Analysts Offer Insights on Healthcare Companies: Eocene (NASDAQ: EOCN) and Dyne Therapeutics (NASDAQ: DYN)
RBC Capital Analyst forecast on DYN
Luca Issi
RBC Capital
RBC Capital
$35→$30
Buy
13.90%
Upside
Reiterated
09/08/26
Dyne Therapeutics (DYN) Gets a Buy from RBC Capital
Chardan Capital Analyst forecast on DYN
Keay Nakae
Chardan Capital
Chardan Capital
$38
Buy
44.27%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Mach7 Technologies (Other OTC: TDMMF) and Dyne Therapeutics (NASDAQ: DYN)
TD Cowen Analyst forecast on DYN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Centene (NYSE: CNC) and Dyne Therapeutics (NASDAQ: DYN)
Evercore ISI Analyst forecast on DYN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
25.28%
Upside
Reiterated
07/27/26
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB) and Dyne Therapeutics (NASDAQ: DYN)
Cantor Fitzgerald Analyst forecast on DYN
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
07/23/26
Dyne Therapeutics initiated with an Overweight at Cantor FitzgeraldDyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
Guggenheim Analyst forecast on DYN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$50
Buy
89.83%
Upside
Reiterated
06/30/26
Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DYN
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$50→$32
Buy
21.49%
Upside
Reiterated
09/30/26
Dyne Therapeutics price target lowered to $32 from $50 at H.C. WainwrightDyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright
Stifel Nicolaus Analyst forecast on DYN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$37
Buy
40.47%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Medios AG (Other OTC: MEDOF) and Dyne Therapeutics (NASDAQ: DYN)
LifeSci Capital Analyst forecast on DYN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$40
Buy
51.86%
Upside
Reiterated
09/30/26
Dyne Therapeutics: Growing Clinical Evidence for z-basivarsen Supports Outperform/Buy Rating and Maintained $40 Price Target
Piper Sandler Analyst forecast on DYN
Edward Tenthoff
Piper Sandler
Piper Sandler
$47
Buy
78.44%
Upside
Reiterated
09/29/26
Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Raymond James Analyst forecast on DYN
Martin Auster
Raymond James
Raymond James
$37
Buy
40.47%
Upside
Reiterated
09/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on DYN
Michael Ulz
Morgan Stanley
Morgan Stanley
$45→$36
Buy
36.67%
Upside
Reiterated
09/09/26
Morgan Stanley Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Robert W. Baird Analyst forecast on DYN
Brian Skorney
Robert W. Baird
Robert W. Baird
$30→$26
Buy
-1.29%
Downside
Reiterated
09/09/26
Dyne Therapeutics price target lowered to $26 from $30 at BairdDyne Therapeutics price target lowered to $26 from $30 at Baird
Jefferies Analyst forecast on DYN
Andrew Tsai
Jefferies
Jefferies
$50
Buy
89.83%
Upside
Reiterated
09/08/26
Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy
J.P. Morgan Analyst forecast on DYN
Tessa Romero
J.P. Morgan
J.P. Morgan
$10
Sell
-62.03%
Downside
Downgraded
09/08/26
Analysts Offer Insights on Healthcare Companies: Eocene (NASDAQ: EOCN) and Dyne Therapeutics (NASDAQ: DYN)
RBC Capital Analyst forecast on DYN
Luca Issi
RBC Capital
RBC Capital
$35→$30
Buy
13.90%
Upside
Reiterated
09/08/26
Dyne Therapeutics (DYN) Gets a Buy from RBC Capital
Chardan Capital Analyst forecast on DYN
Keay Nakae
Chardan Capital
Chardan Capital
$38
Buy
44.27%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Mach7 Technologies (Other OTC: TDMMF) and Dyne Therapeutics (NASDAQ: DYN)
TD Cowen Analyst forecast on DYN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
07/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Centene (NYSE: CNC) and Dyne Therapeutics (NASDAQ: DYN)
Evercore ISI Analyst forecast on DYN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
25.28%
Upside
Reiterated
07/27/26
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB) and Dyne Therapeutics (NASDAQ: DYN)
Cantor Fitzgerald Analyst forecast on DYN
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
07/23/26
Dyne Therapeutics initiated with an Overweight at Cantor FitzgeraldDyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
Guggenheim Analyst forecast on DYN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$50
Buy
89.83%
Upside
Reiterated
06/30/26
Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
OMCLOmnicell
LGNDLigand Pharma
KURAKura Oncology
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

3 Months
Paul MatteisStifel Nicolaus
Success Rate
14/26 ratings generated profit
54%
Average Return
+5.46%
Copying Paul Matteis's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +5.46% per trade.
1 Year
Keay NakaeChardan Capital
Success Rate
10/17 ratings generated profit
59%
Average Return
+46.40%
Copying Keay Nakae's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +46.40% per trade.
2 Years
Keay NakaeChardan Capital
Success Rate
8/17 ratings generated profit
47%
Average Return
+47.56%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +47.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
20
24
13
17
12
Buy
1
6
6
7
2
Hold
1
3
2
2
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
1
1
total
22
33
21
27
15
In the current month, DYN has received 14 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. DYN average Analyst price target in the past 3 months is 34.67.
Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.91 with a range of -$1.09 to -$0.73. The previous quarter’s EPS was -$1.08. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
Next quarter’s earnings estimate for DYN is -$0.91 with a range of -$1.09 to -$0.73. The previous quarter’s EPS was -$1.08. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?
Based on analyst ratings, Dyne Therapeutics’s 12-month average price target is 34.67.
    What is DYN’s upside potential, based on the analysts’ average price target?
    Dyne Therapeutics has 31.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DYN a Buy, Sell or Hold?
          Dyne Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Dyne Therapeutics’s price target?
            The average price target for Dyne Therapeutics is 34.67. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $10.00. The average price target represents 31.61% Increase from the current price of $26.34.
              What do analysts say about Dyne Therapeutics?
              Dyne Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of DYN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.